Literature DB >> 18632867

Llama-derived single-chain antibody fragments directed to rotavirus VP6 protein possess broad neutralizing activity in vitro and confer protection against diarrhea in mice.

Lorena Garaicoechea1, Aurelien Olichon, Gisela Marcoppido, Andrés Wigdorovitz, Marina Mozgovoj, Linda Saif, Thomas Surrey, Viviana Parreño.   

Abstract

Group A rotavirus is one of the most common causes of severe diarrhea in human infants and newborn animals. Rotavirus virions are triple-layered particles. The outer capsid proteins VP4 and VP7 are highly variable and represent the major neutralizing antigens. The inner capsid protein VP6 is conserved among group A rotaviruses, is highly immunogenic, and is the target antigen of most immunodiagnosis tests. Llama-derived single-chain antibody fragments (VHH) are the smallest molecules with antigen-binding capacity and can therefore be expected to have properties different from conventional antibodies. In this study a library containing the VHH genes of a llama immunized with recombinant inner capsid protein VP6 was generated. Binders directed to VP6, in its native conformation within the viral particle, were selected and characterized. Four selected VHH directed to conformational epitopes of VP6 recognized all human and animal rotavirus strains tested and could be engineered for their use in immunodiagnostic tests for group A rotavirus detection. Three of the four VHH neutralized rotavirus in vivo independently of the strain serotype. Furthermore, this result was confirmed by in vivo partial protection against rotavirus challenge in a neonatal mouse model. The present study demonstrates for the first time a broad neutralization activity of VP6 specific VHH in vitro and in vivo. Neutralizing VHH directed to VP6 promise to become an essential tool for the prevention and treatment of rotavirus diarrhea.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18632867      PMCID: PMC2546978          DOI: 10.1128/JVI.00436-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion.

Authors:  Blaise Corthésy; Yann Benureau; Clémentine Perrier; Cynthia Fourgeux; Nathalie Parez; Harry Greenberg; Isabelle Schwartz-Cornil
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

2.  Protection of mice against rotavirus challenge following intradermal DNA immunization by Biojector needle-free injection.

Authors:  Anthony H-C Choi; Kristi Smiley; Mitali Basu; Monica M McNeal; Mingyuan Shao; Judy A Bean; John D Clements; Richard R Stout; Richard L Ward
Journal:  Vaccine       Date:  2007-01-22       Impact factor: 3.641

3.  Immunization with baculovirus-expressed VP4 protein passively protects against simian and murine rotavirus challenge.

Authors:  E R Mackow; P T Vo; R Broome; D Bass; H B Greenberg
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

4.  Passive immunization of guinea pigs with llama single-domain antibody fragments against foot-and-mouth disease.

Authors:  M M Harmsen; C B van Solt; H P D Fijten; L van Keulen; R A Rosalia; K Weerdmeester; A H M Cornelissen; M G M De Bruin; P L Eblé; A Dekker
Journal:  Vet Microbiol       Date:  2006-10-28       Impact factor: 3.293

5.  Assembly of recombinant rotavirus proteins into virus-like particles and assessment of vaccine potential.

Authors:  M J Redmond; M K Ijaz; M D Parker; M I Sabara; D Dent; E Gibbons; L A Babiuk
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

6.  Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity.

Authors:  J W Burns; M Siadat-Pajouh; A A Krishnaney; H B Greenberg
Journal:  Science       Date:  1996-04-05       Impact factor: 47.728

7.  The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi.

Authors:  Vivi Joosten; Christien Lokman; Cees AMJJ Van Den Hondel; Peter J Punt
Journal:  Microb Cell Fact       Date:  2003-01-30       Impact factor: 5.328

8.  Passive immunity to bovine rotavirus in newborn calves fed colostrum supplements from cows immunized with recombinant SA11 rotavirus core-like particle (CLP) or virus-like particle (VLP) vaccines.

Authors:  F M Fernandez; M E Conner; D C Hodgins; A V Parwani; P R Nielsen; S E Crawford; M K Estes; L J Saif
Journal:  Vaccine       Date:  1998-03       Impact factor: 3.641

9.  Modulation by colostrum-acquired maternal antibodies of systemic and mucosal antibody responses to rotavirus in calves experimentally challenged with bovine rotavirus.

Authors:  V Parreño; C Béjar; A Vagnozzi; M Barrandeguy; V Costantini; M I Craig; L Yuan; D Hodgins; L Saif; F Fernández
Journal:  Vet Immunol Immunopathol       Date:  2004-07       Impact factor: 2.046

10.  Development of a murine model to study the pathogenesis of rotavirus infection.

Authors:  M K Ijaz; D Dent; D Haines; L A Babiuk
Journal:  Exp Mol Pathol       Date:  1989-10       Impact factor: 3.362

View more
  40 in total

1.  Translational fusion and redirection to thylakoid lumen as strategies to improve the accumulation of a camelid antibody fragment in transplastomic tobacco.

Authors:  Ezequiel M Lentz; Lorena Garaicoechea; E Federico Alfano; Viviana Parreño; Andrés Wigdorovitz; Fernando F Bravo-Almonacid
Journal:  Planta       Date:  2012-04-24       Impact factor: 4.116

2.  Rotavirus VP7 epitope chimeric proteins elicit cross-immunoreactivity in guinea pigs.

Authors:  Bingxin Zhao; Xiaoxia Pan; Yumei Teng; Wenyue Xia; Jing Wang; Yuling Wen; Yuanding Chen
Journal:  Virol Sin       Date:  2015-10-10       Impact factor: 4.327

Review 3.  Immune responses to rotavirus infection and vaccination and associated correlates of protection.

Authors:  Ulrich Desselberger; Hans-Iko Huppertz
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

4.  Design and Antigenic Epitopes Prediction of a New Trial Recombinant Multiepitopic Rotaviral Vaccine: In Silico Analyses.

Authors:  Sima Jafarpour; Hoda Ayat; Ali Mohammad Ahadi
Journal:  Viral Immunol       Date:  2015-05-12       Impact factor: 2.257

5.  The 13th International Double-Stranded RNA Virus Symposium, Houffalize, Belgium, 24 to 28 September 2018.

Authors:  Ulrich Desselberger
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

6.  Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1.

Authors:  Willie W L Koh; Soren Steffensen; Maria Gonzalez-Pajuelo; Bart Hoorelbeke; Andrea Gorlani; Agnieszka Szynol; Anna Forsman; Marlén M I Aasa-Chapman; Hans de Haard; Theo Verrips; Robin A Weiss
Journal:  J Biol Chem       Date:  2010-04-16       Impact factor: 5.157

7.  Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.

Authors:  Suvi Lappalainen; Kirsi Tamminen; Timo Vesikari; Vesna Blazevic
Journal:  Hum Vaccin Immunother       Date:  2013-06-18       Impact factor: 3.452

8.  Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection.

Authors:  Daisuke Tokuhara; Beatriz Álvarez; Mio Mejima; Tomoko Hiroiwa; Yuko Takahashi; Shiho Kurokawa; Masaharu Kuroda; Masaaki Oyama; Hiroko Kozuka-Hata; Tomonori Nochi; Hiroshi Sagara; Farah Aladin; Harold Marcotte; Leon G J Frenken; Miren Iturriza-Gómara; Hiroshi Kiyono; Lennart Hammarström; Yoshikazu Yuki
Journal:  J Clin Invest       Date:  2013-08-08       Impact factor: 14.808

Review 9.  Single domain antibodies: promising experimental and therapeutic tools in infection and immunity.

Authors:  Janusz Wesolowski; Vanina Alzogaray; Jan Reyelt; Mandy Unger; Karla Juarez; Mariela Urrutia; Ana Cauerhff; Welbeck Danquah; Björn Rissiek; Felix Scheuplein; Nicole Schwarz; Sahil Adriouch; Olivier Boyer; Michel Seman; Alexei Licea; David V Serreze; Fernando A Goldbaum; Friedrich Haag; Friedrich Koch-Nolte
Journal:  Med Microbiol Immunol       Date:  2009-06-16       Impact factor: 3.402

10.  Sang Froid in a time of trouble: is a vaccine against HIV possible?

Authors:  Stanley A Plotkin
Journal:  J Int AIDS Soc       Date:  2009-02-02       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.